Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist.
Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. for $1.075 billion, announced in August 2023.
Also Read: European Drug Agency Supports Novo Nordisk’s Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure.
The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg, and 50 mg of monlunabant compared to placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome.
From a baseline body weight of 110.1 kg, ...
